Reinhard Vogt

Reinhard Vogt General Information

Biography

Mr. Reinhard Vogt serves as a Partner at Avant Bio. He also serves as a Venture Partner at Dynamk Capital. He serves as Chairman at Bionter. He serves as a Board Member at Vectron Biosolutions and Lucid Scientific. He brings a wealth of industry knowledge, technology deal-side expertise, and numerous technology licenses, acquisitions, and integrations derived from over 30 years at one of the industry's largest players. For investors and portfolio companies, this means a winning combination of commercial and operational support owed to his experience with more than a dozen high-profile, accretive deals throughout his time at Sartorius Stedim Biotech S.A (Sartorius), a leading international partner to biotechnology and pharmaceutical companies, providing critical solutions for research, development, and manufacturing. Beginning in the 1990s and up to his last role as Executive VP and Member of the Board of Sartorius, he was instrumental in building and transforming Sartorius' filtration business from €30 million in revenue to what is today the Sartorius Bioprocess Business of around €2.8 billion in revenue. He led the transformation of Sartorius' strategy to become the leader in single-use bioprocessing technologies and revolutionized how biologics are manufactured. His track record includes technology licenses and acquisitions ranging from the Stedim SA and B.Braun Biotech transactions to more recent deals, including TAP Biosystems, Cellca, BioOutsource, and Umetrics. He served as Director of 15 companies and Sartorius affiliates in his career and has also established operations in Australia, China, India, Korea, and Turkey.